SIETES :: 92848 citas

Resultados de la búsqueda por COMERCIALIZACIÓN REFINAR BÚSQUEDA

21.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

22.

Thomas K. Celgene to pay $280 Million to settle fraud suit over cancer drugs. N Y Times (Print) 2017:1. [Ref.ID 101924]

23.

Armstrong D. Kentucky Senate president urges release of secret OxyContin records. STAT 2017:28 de junio. [Ref.ID 101657]

24.

Anónimo. Gilead’s hepatitis C drug sales decline. DIA Daily 2016:11. [Ref.ID 100874]

25.

Anónimo. Amgen unlikely to launch adalimumab biosimilar in 2017 due to litigation. DIA Daily 2016:6. [Ref.ID 100871]

26.

Welch WVa. Secret trove reveals bold ‘crusade’ to make OxyContin a blockbuster. STAT 2016:1. [Ref.ID 100698]

27.

Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]

28.

Anónimo. La falsa transparencia y el lavado de cara de la industria farmacéutica. NoGracias 2016:1 de julio. [Ref.ID 100507]

29.

O'Dowd A. Drug company is suspended from UK industry body after “deception on a grand scale”. BMJ 2016;353:i3574. [Ref.ID 100449]

30.

Dyer O. Physician whistleblower is awarded $59m in Pfizer settlement. BMJ 2016;352:i1195. [Ref.ID 100326]

31.

Anónimo. Valeant “predatorily priced” female libido drug, investors claim. DIA Daily 2016:1. [Ref.ID 100042]

32.

McCarthy M. Novartis agrees to pay $390m in US kickback case. BMJ 2015;351:h5784. [Ref.ID 99637]

33.

Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]

34.

Anónimo. Teva Pharmaceuticals settles FTC’s claim against Cephalon for $1.2 billion. DIA Daily 2015:29 de mayo. [Ref.ID 99107]

35.

Gulland A. Top drug companies are making drugs more accessible but are also guilty of corruption, report says. BMJ 2014;349:g6834. [Ref.ID 98443]

36.

Dyer C. UK needs database of payments from industry to doctors, conference hears. BMJ 2014;349:g6197. [Ref.ID 98282]

37.

Anónimo. Analysis: drug companies increasingly marketing to hospital administrators. DIA Daily 2014:25 de septiembre. [Ref.ID 97956]

38.

Moore A, Wiffen P, Eccleston Ch, Lunn M, Hughes R, Williams A, Aldington D, Kalso E. Duloxetine: Andrew Moore and colleagues reply to Des Spence. BMJ 2014;348:g1490. [Ref.ID 97331]

39.

McCarthy M. Drug company staff fretted when in-house paper's conclusion clashed with the drug's marketing claims. BMJ 2014;348:g1505. [Ref.ID 97328]

40.

Spence D. Bad medicine: the rise of duloxetine. BMJ 2014;348:g139. [Ref.ID 97247]